Hypofractioned radiotherapy in prostate cancer: is it the next step?

References

• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64(1):9-29
   PubMed Web of Science ®Google Scholar
• Paquette EL, Sun L, Paquette LR, et al. Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. Urology 2002;60(5):756-9
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: prostate. V.2.2014. Available from: www.nccn.org [Last accessed 28 July 2014]
   Google Scholar
• Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/American college of radiology 95-09. J Clin Oncol 2010;28(7):1106-11
   PubMed Web of Science ®Google Scholar
• Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70(1):67-74
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Pei X, Chou JF, et al. Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol 2011;60(6):1133-9
   PubMed Web of Science ®Google Scholar
• Thames HD, Suit HD. Tumor radioresponsiveness versus fractionation sensitivity. Int J Radiat Oncol Biol Phys 1986;12(4):687-91
   PubMedGoogle Scholar
• Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989;62(740):679-94
   PubMed Web of Science ®Google Scholar
• Leborgne F, Fowler J, Leborgne JH, Mezzera J. Later outcomes and alpha/beta estimate from hypofractionated conformal three-dimensional radiotherapy versus standard fractionation for localized prostate cancer. Int J Radiat Oncol Biol Phys 2012;82(3):1200-7
   PubMed Web of Science ®Google Scholar
• Fowler JF, Ritter MA, Chappell RJ, Brenner DJ. What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys 2003;56(4):1093-104
   PubMed Web of Science ®Google Scholar
• Brenner DJ. The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction. Semin Radiat Oncol 2008;18(4):234-9
   PubMed Web of Science ®Google Scholar
• Wang JZ, Guerrero M, Li XA. How low is the alpha/beta ratio for prostate cancer? Int J Radiat Oncol Biol Phys 2003;55(1):194-203
   PubMedGoogle Scholar
• Kirkpatrick JP, Meyer JJ, Marks LB. The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol 2008;18(4):240-3
   PubMed Web of Science ®Google Scholar
• Park C, Papiez L, Zhang S, et al. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 2008;70(3):847-52
   PubMed Web of Science ®Google Scholar
• Hall EJ, Brenner DJ. The radiobiology of radiosurgery: rationale for different treatment regimes for AVMs and malignancies. Int J Radiat Oncol Biol Phys 1993;25(2):381-5
   PubMed Web of Science ®Google Scholar
• D’Amico AV. Prostate cancer: where we have been, where we are, and where we are going. Semin Radiat Oncol 2013;23(3):155-6
   PubMedGoogle Scholar
• Zelefsky MJ, Kollmeier M, Cox B, et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2012;84(1):125-9
   PubMed Web of Science ®Google Scholar
• Engels B, Tournel K, Soete G, Storme G. Assessment of rectal distention in radiotherapy of prostate cancer using daily megavoltage CT image guidance. Radiother Oncol J Eur Soc Ther Radiol Oncol 2009;90(3):377-81
   PubMedGoogle Scholar
• Kupelian PA, Willoughby TR, Reddy CA, et al. Impact of image guidance on outcomes after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;70(4):1146-50
   PubMedGoogle Scholar
• Hanna SA, Neves-Junior WF, Marta GN, et al. Role of intra-orperiprostatic calcifications in image-guided radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2012;82(3):1208-16
   PubMedGoogle Scholar
• Lukka H, Hayter C, Julian JA, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 2005;23(25):6132-8
   PubMed Web of Science ®Google Scholar
• Yeoh EE, Botten RJ, Butters J, et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys 2011;81(5):1271-8
   PubMed Web of Science ®Google Scholar
• Kupelian PA, Willoughby TR, Reddy CA, et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 2007;68(5):1424-30
   PubMed Web of Science ®Google Scholar
• Arcangeli S, Strigari L, Gomellini S, et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012;84(5):1172-8
   PubMed Web of Science ®Google Scholar
• Pollack A, Hanlon AL, Horwitz EM, et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 2006;64(2):518-26
   PubMed Web of Science ®Google Scholar
• Pollack A, Walker G, Horwitz EM, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J Clin Oncol 2013;31(31):3860–8
   PubMedGoogle Scholar
• Kuban DA, Nogueras-Gonzalez GM, Hamblin L, et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. Int J Radiat Oncol Biol Phys 2010;78(3):S58-9
   PubMed Web of Science ®Google Scholar
• Lee WR. Prostate cancer and the hypofractionation hypothesis. J Clin Oncol 2013;31(31):3849-51
   PubMedGoogle Scholar
• Dearnaley D, Syndikus I, Sumo G, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 2012;13(1):43-54
   PubMed Web of Science ®Google Scholar
• Radiation therapy in treating patients with stage ii prostate cancer. http://clinicaltrials.gov/show/NCT00331773
   Google Scholar
• PROFIT - prostate fractionated irradiation trial. http://clinicaltrials.gov/show/NCT00304759
   Google Scholar
• Cabrera AR, Lee WR. Hypofractionation for clinically localized prostate cancer. Semin Radiat Oncol 2013;23(3):191-7
   PubMedGoogle Scholar
• Madsen BL, His RA, Pham HT, et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007;67:1099-105
   PubMed Web of Science ®Google Scholar
• King CR, Freeman D, Kaplan I, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Int J Radiat Oncol Biol Phys 2013;109:217-21
   Google Scholar
• King CR, Collins S, Fuller D, et al. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. Int J Radiat Oncol Biol Phys 2013;87:939-45
   PubMedGoogle Scholar
• Loblaw A, Cheung P, D’Alimonte L, et al. Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes. Radiother Oncol 2013;107:153-8
   PubMed Web of Science ®Google Scholar
• Radiation therapy in treating patients with prostate cancer. http://clinicaltrials.gov/show/NCT01434290
   Google Scholar
• King CR, Brooks JD, Gill H, et al. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 2009;73(4):1043-8
   PubMed Web of Science ®Google Scholar
• Katz AJ, Santoro M, Ashley R, et al. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol 2010;10:1
   PubMed Web of Science ®Google Scholar
• McBride SM, Wong DS, Dombrowski JJ, et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer 2012;118:3681-90
   PubMed Web of Science ®Google Scholar
• Bolzicco G, Favretto MS, Satariano N, et al. A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy. BMC Urol 2013;13:49
   PubMed Web of Science ®Google Scholar